We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+9.48%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$836M
AUM Growth
+$4.91M
Cap. Flow
-$16.6M
Cap. Flow %
-1.98%
Top 10 Hldgs %
38.74%
Holding
112
New
6
Increased
28
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$11.9M
2
KYNB
Kyntra Bio
KYNB
+$9.69M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$9.43M
4
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$6.67M
5
IMMU
Immunomedics Inc
IMMU
+$6.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$17M
2
UNH icon
UnitedHealth
UNH
+$8.53M
3
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$5.93M
4
ADMS
Adamas Pharmaceuticals
ADMS
+$5.75M
5
PODD icon
Insulet
PODD
+$5.61M

Sector Composition

Rank Sector Weight
1 Healthcare 85.37%
2 Industrials 2.83%
3 Technology 2.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
76
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$203K 0.02%
4,051
– –
TLPH icon
77
Talphera
TLPH
$67.5M
$187K 0.02%
3,689
– –
CCXI
78
DELISTED
ChemoCentryx, Inc.
CCXI
$166K 0.02%
17,811
– –
ATRS
79
DELISTED
Antares Pharma, Inc.
ATRS
$156K 0.02%
47,280
– –
RVNC
80
DELISTED
Revance Therapeutics, Inc.
RVNC
$146K 0.02%
11,234
– –
PTGX icon
81
Protagonist Therapeutics
PTGX
$8.8B
$138K 0.02%
11,400
– –
CTMX icon
82
CytomX Therapeutics
CTMX
$701M
$113K 0.01%
10,058
– –
LITS
83
Lite Strategy Inc
LITS
$33M
$111K 0.01%
2,227
– –
NBRV
84
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$93K 0.01%
153
– –
SYRE icon
85
Spyre Therapeutics
SYRE
$8.68B
$89K 0.01%
518
– –
MRNS
86
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$70K 0.01%
4,200
– –
BLRX
87
BioLineRX
BLRX
$12.2M
$65K 0.01%
297
– –
ABEO icon
88
Abeona Therapeutics
ABEO
$343M
$61K 0.01%
507
– –
CRVS icon
89
Corvus Pharmaceuticals
CRVS
$1.12B
$47K 0.01%
12,594
– –
CLSD
90
DELISTED
Clearside Biomedical
CLSD
$25K ﹤0.01%
1,731
– –
SRRA
91
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$23K ﹤0.01%
1,027
-2,482
-71% -$120K
TTPH
92
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$19K ﹤0.01%
1,991
– –
CDTX
93
DELISTED
Cidara Therapeutics
CDTX
– –
-1,272
Closed -$67K
CNC icon
94
Centene
CNC
$31.6B
– –
-4,180
Closed -$222K
CYTK icon
95
Cytokinetics
CYTK
$10.8B
– –
-15,582
Closed -$126K
ELV icon
96
Elevance Health
ELV
$83.7B
– –
-3,361
Closed -$965K
HCA icon
97
HCA Healthcare
HCA
$92.8B
– –
-5,316
Closed -$693K
HUM icon
98
Humana
HUM
$46.7B
– –
-1,841
Closed -$490K
JNJ icon
99
Johnson & Johnson
JNJ
$643B
– –
-17,799
Closed -$2.49M
MDGL icon
100
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-42,487
Closed -$5.32M
1 2 3
4
5

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
AAA
AG Asset Advisory Los Angeles, California $121M AUM 10.78% 1-Year Est. Return
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return

Sectoral Asset Management's Q2 2019 Portfolio in Review

As of Q2 2019, Sectoral Asset Management held 112 positions worth $836M, up 0.59% from $831M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Sectoral Asset Management's Q2 2019 filing shows 6 new, 28 increased, 28 reduced and 20 closed positions. Its largest new stake was Alexion Pharmaceuticals: 73,199 shares worth $9.59M. The largest sale was Celgene Corp, an estimated $17M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 85% a quarter earlier, followed by Industrials and Technology.

  • Sectoral Asset Management's largest Q2 2019 buy was Alexion Pharmaceuticals: 73,199 shares worth $9.59M.
  • Sectoral Asset Management added most to Tandem Diabetes Care in Q2 2019, an estimated $11.9M increase.
  • Sectoral Asset Management's biggest Q2 2019 reduction was Insulet, cutting an estimated $5.61M.
  • Sectoral Asset Management fully exited Celgene Corp in Q2 2019, selling an estimated $17M.
  • Sectoral Asset Management's ten largest holdings make up 39% of its $836M portfolio in Q2 2019.
  • Sectoral Asset Management opened 6 new positions and closed 20 in Q2 2019.
  • Sectoral Asset Management's portfolio value rose 0.59% quarter-over-quarter to $836M.

Based on Sectoral Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.